Associations of physical fitness and physical activity with sleep among middle-aged women.

BACKGROUND: Sleep is an important component of health. Sleep disturbances increase in women as they enter menopause. Physical activity has been associated with improved sleep among older populations. The purpose of this study was to determine if physical activity and/or physical fitness are associated with sleep quantity and quality in middle-aged women. METHODS: This study recruited 114 healthy women, aged 30-55 (43±8 y) from Saskatoon, Saskatchewan, from 2015-2019. Sleep quantity and quality were evaluated. Participants were classified on their aerobic fitness, based on estimated peak aerobic capacity, as high or low grip strength and, as active or inactive. RESULTS: The high aerobic fitness group had a greater mean sleep duration of 7.04±1.02 h compared to the low fit group 6.61±1.00 h after adjusting for age, Body Mass Index, waist circumference and menstrual status (P=0.01). The percentage of high aerobic fitness women who felt rested was greater than low aerobic fitness women (67±6% vs. 45±7%, P=0.03), after adjusting for age, Body Mass Index, waist circumference and menstrual status. Our study found a significant difference between women with higher aerobic fitness levels getting more sleep each night and feeling more rested. CONCLUSIONS: The continued examination of physical fitness and its relationship to sleep holds importance for women's health.

A Randomized, Double-blind, Placebo-Controlled Crossover Trial of Oxymorphone Hydrochloride and Propoxyphene/Acetaminophen Combination for the Treatment of Neurogenic Claudication Associated With Lumbar Spinal Stenosis.

STUDY DESIGN: Randomized, double-blind, placebo-controlled, single-dose crossover study. OBJECTIVE: To test the analgesic efficacy of oxymorphone hydrochloride (OH) and propoxyphene/acetaminophen (PA) for patients with neurogenic claudication associated with lumbar spinal stenosis. SUMMARY OF BACKGROUND DATA: Although opioids are often prescribed for neurogenic claudication, no randomized controlled studies support their efficacy for this condition. Patients with neurogenic claudication are generally excluded from clinical trials or included with patients who have nonspecific chronic low back pain, yielding a heterogeneous study population with very different pathophysiologies and clinical presentations. METHODS: Participants received a single dose of each of the 3 treatments in random order. Treatments were separated by at least 3-day washout periods. The primary outcome variable was the time to first treadmill walking-induced moderate pain (≥4 out of 10 on a Numeric Rating Scale) (Tfirst) assessed 90 minutes after treatment administration. Secondary outcome measures included patient global assessment of low back pain, Roland-Morris Disability Questionnaire, Modified Brief Pain Inventory-Short Form, Oswestry Disability Index, and Swiss Spinal Stenosis Questionnaire. RESULTS: The study was prematurely terminated because of the removal of PA from the US market. Twenty-four patients were randomized; 21 completed all 3 treatment periods. There were no significant differences among the treatment groups with respect to the median Tfirst (OH-placebo: median [98.3% confidence limits]=-0.25 min [-6.54, 5.00]; PA-placebo: 0.02 min [-7.65, 4.90]; OH-PA: -0.27 min [-5.56, 6.66]). CONCLUSION: This trial failed to demonstrate a benefit of OH or PA in patients experiencing neurogenic claudication. Considering the potential negative side effects of chronic opioid use, additional research is necessary to evaluate the efficacy of sustained opioid treatment specifically for neurogenic claudication. LEVEL OF EVIDENCE: 2.